First BCL-2 Inhibitor Approved for Mantle Cell Lymphoma - PubMed
4 hours ago
- #Cancer therapy
- #BCL-2 inhibitor
- #Mantle cell lymphoma
- Sonrotoclax is the first BCL-2 inhibitor approved for relapsed or refractory mantle cell lymphoma.
- It offers a distinct option for patients who have undergone BTK inhibitor therapy.
- Sonrotoclax binds BCL-2 with over 10 times greater potency than venetoclax and may have a better platelet toxicity profile.
- Phase III trials are comparing it head-to-head with venetoclax for chronic lymphocytic leukemia, potentially reshaping treatment.